SCHEMBL22249332

SCHEMBL22249332

CO[C@@H]1C[C@H](N)C[C@H]1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22249331 1.00
SCHEMBL1737561 0.84
SCHEMBL7793301 0.81 KDM1A (0.31)
SCHEMBL13210414 0.77 FUCA1 (0.32)
SCHEMBL12952243 0.76 GSR (0.37)
SCHEMBL5494425 0.74
SCHEMBL22084028 0.74
SCHEMBL12653860 0.74
SCHEMBL12653858 0.74
SCHEMBL13493464 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187706-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC. (US) 2025-01-07 US disclosed
EP-3911416-B1 SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER INNATE TUMOR IMMUNITY INC (US) 2024-06-12 EP disclosed
US-20220089571-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY INC (US) 2022-03-24 US disclosed
US-20220089571-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY INC (US) 2022-03-24 US disclosed
CN-113301963-A Substituted quinazolines as NLRP3 modulators for the treatment of cancer 先天肿瘤免疫公司 2021-08-24 CN disclosed
WO-2020150113-A1 SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER INNATE TUMOR IMMUNITY, INC. (US) 2020-07-23 WO disclosed